324 related articles for article (PubMed ID: 20560147)
1. Peptide-labeled supramolecular aggregates as selective doxorubicin carriers for delivery to tumor cells.
Morisco A; Accardo A; Tesauro D; Palumbo R; Benedetti E; Morelli G
Biopolymers; 2011; 96(1):88-96. PubMed ID: 20560147
[TBL] [Abstract][Full Text] [Related]
2. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
[TBL] [Abstract][Full Text] [Related]
3. Coformulated N-octanoyl-glucosylceramide improves cellular delivery and cytotoxicity of liposomal doxorubicin.
Veldman RJ; Koning GA; van Hell A; Zerp S; Vink SR; Storm G; Verheij M; van Blitterswijk WJ
J Pharmacol Exp Ther; 2005 Nov; 315(2):704-10. PubMed ID: 16040815
[TBL] [Abstract][Full Text] [Related]
4. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
[TBL] [Abstract][Full Text] [Related]
5. A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor.
He X; Na MH; Kim JS; Lee GY; Park JY; Hoffman AS; Nam JO; Han SE; Sim GY; Oh YK; Kim IS; Lee BH
Mol Pharm; 2011 Apr; 8(2):430-8. PubMed ID: 21222482
[TBL] [Abstract][Full Text] [Related]
6. Increasing the antitumor efficacy of doxorubicin-loaded liposomes with peptides anchored via a chelator lipid.
Herringson TP; Altin JG
J Drug Target; 2011 Sep; 19(8):681-9. PubMed ID: 21142652
[TBL] [Abstract][Full Text] [Related]
7. Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors.
van Lummel M; van Blitterswijk WJ; Vink SR; Veldman RJ; van der Valk MA; Schipper D; Dicheva BM; Eggermont AM; ten Hagen TL; Verheij M; Koning GA
FASEB J; 2011 Jan; 25(1):280-9. PubMed ID: 20876209
[TBL] [Abstract][Full Text] [Related]
8. New chimeric advanced Drug Delivery nano Systems (chi-aDDnSs) as doxorubicin carriers.
Gardikis K; Tsimplouli C; Dimas K; Micha-Screttas M; Demetzos C
Int J Pharm; 2010 Dec; 402(1-2):231-7. PubMed ID: 20934501
[TBL] [Abstract][Full Text] [Related]
9. Accumulation, internalization and therapeutic efficacy of neuropilin-1-targeted liposomes.
Paoli EE; Ingham ES; Zhang H; Mahakian LM; Fite BZ; Gagnon MK; Tam S; Kheirolomoom A; Cardiff RD; Ferrara KW
J Control Release; 2014 Mar; 178():108-17. PubMed ID: 24434424
[TBL] [Abstract][Full Text] [Related]
10. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
11. Redox responsive liposomal nanohybrid cerasomes for intracellular drug delivery.
Zhou G; Li L; Xing J; Jalde S; Li Y; Cai J; Chen J; Liu P; Gu N; Ji M
Colloids Surf B Biointerfaces; 2016 Dec; 148():518-525. PubMed ID: 27690240
[TBL] [Abstract][Full Text] [Related]
12. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination.
Fonseca NA; Gomes-da-Silva LC; Moura V; Simões S; Moreira JN
J Control Release; 2014 Dec; 196():122-31. PubMed ID: 25305563
[TBL] [Abstract][Full Text] [Related]
14. A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models.
Zhang J; Jin W; Wang X; Wang J; Zhang X; Zhang Q
Mol Pharm; 2010 Aug; 7(4):1159-68. PubMed ID: 20524673
[TBL] [Abstract][Full Text] [Related]
15. Effects of lipid composition on the properties of doxorubicin-loaded liposomes.
Sakai-Kato K; Nanjo K; Kawanishi T; Okuda H; Goda Y
Ther Deliv; 2015 Jul; 6(7):785-94. PubMed ID: 26228772
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q
Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608
[TBL] [Abstract][Full Text] [Related]
17. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticles exposing neurotensin tumor-specific drivers.
Falciani C; Brunetti J; Lelli B; Accardo A; Tesauro D; Morelli G; Bracci L
J Pept Sci; 2013 Apr; 19(4):198-204. PubMed ID: 23436714
[TBL] [Abstract][Full Text] [Related]
19. Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: a potential theranostic agent.
Accardo A; Salsano G; Morisco A; Aurilio M; Parisi A; Maione F; Cicala C; Tesauro D; Aloj L; De Rosa G; Morelli G
Int J Nanomedicine; 2012; 7():2007-17. PubMed ID: 22619538
[TBL] [Abstract][Full Text] [Related]
20. The liposomal formulation of doxorubicin.
Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]